Issued on behalf of Aleen Inc.
VANCOUVER – Equity Insider News Commentary – Healthcare providers are integrating AI and bioinformatics to predict disease risks and personalize treatment plans based on genetic makeup, lifestyle factors, and environmental data[1]. The artificial intelligence in healthcare market is projected to expand from $17.2 billion in 2025 to $77.2 billion by 2035 as digital transformation and data-driven medical systems reshape patient access to care[2]. Platforms processing personal health data to deliver actionable insights are capturing this momentum across wellness ecosystems, clinical operations, early disease detection, and drug discovery, with Hims & Hers Health, Inc. (NYSE: HIMS), Butterfly Network, Inc. (NYSE: BFLY), NANOX Imaging Ltd. (NASDAQ: NNOX), and Schrödinger, Inc. (NASDAQ: SDGR). Alongside these developments in the broader industry, Aleen Inc. (CSE: ALEN-U) is advancing its position within the digital wellness segment, focusing strictly on non-medical, user-friendly analytics that help individuals better understand their everyday well-being patterns.
While 48% of clinicians have used AI tools, organizations are expanding from administrative automation to clinical workflow optimization, creating favorable timing for companies delivering intelligent wellness ecosystems and precision medicine infrastructure before major institutional waves reshape healthcare delivery[3].
Aleen Inc. (CSE: ALEN-U), a Canadian digital wellness company, has announced it is advancing development of its Smart Analytics feature, designed to help users interpret wellness data clearly and responsibly. The system transforms raw information into structured, accessible insights, emphasizing transparency and personal reflection to encourage users to observe patterns rather than interpret them medically .
“Our current focus is on understanding how an analytical tool can responsibly support everyday well-being, while staying entirely outside the realm of diagnostic or medical functions,” said Anastasiia Kalashnik, PR Specialist of Aleen. “We are laying the groundwork for a feature that inspires awareness and self-reflection, not prescribes actions.”
The company previously announced the development of a personal account system designed to redefine how individuals interact with their wellness data. The upcoming personal account will serve as an intuitive hub where users can seamlessly upload, manage, and visualize their non-medical well-being information. The Smart Analytics feature now in full-scale development will work in conjunction with these personal accounts to provide users with deeper understanding of their general wellness patterns.
Before that, Aleen announced it was beginning early concept testing for smart wellness analytics, with research highlighting three recurring user expectations: clear visualization of personal wellness patterns, strong privacy safeguards and control over shared information, and simple, non-medical interpretation of structured inputs.
Based in Ontario, Aleen went public in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The company operates in a rapidly expanding market, with the global digital wellness sector currently valued at approximately $12.87 billion in 2025 and projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen is positioned to capture a portion of this expanding demand.
The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen Inc.’s technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access.
Looking ahead to 2026, Aleen plans to launch the personal user accounts currently in development alongside the smart analytics features being tested. With 12,643,300 common shares currently issued and outstanding, Aleen continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman. The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities.
CONTINUED… Read this and more news for Aleen Inc. at:
Hims & Hers Health, Inc. (NYSE: HIMS) introduced Labs, a comprehensive testing experience that measures key health markers over time and provides doctor-developed action plans to power real shifts in health outcomes, addressing a critical gap in a healthcare system where 70% of medical decisions depend on lab tests. The new offering features two plans: Base at $199 per year includes one yearly blood draw capturing 50 biomarker tests across 9 categories, while Advanced at $499 per year includes two yearly blood draws capturing over 120 biomarker tests across 10 key categories, both featuring doctor-developed action plans and access to personalized treatment plans if deemed appropriate by healthcare providers.
The company expects to expand the offering over time with plans to introduce at-home testing devices, additional biomarker tests in areas like bone and brain health, and advanced diagnostics that detect chronic and life-threatening conditions.
Labs not only helps keep customers healthier but powers a more intelligent Hims & Hers platform that helps providers make decisions more tailored to the individual, with the platform providing insights across heart health, metabolism, hormones, inflammation, and stress for proactive health management.
Butterfly Network, Inc. (NYSE: BFLY) launched Compass AI™, its AI-powered operating system built for compliant, scalable, revenue-ready point-of-care ultrasound programs that enables documentation compliance rates of up to 94% without adding work for clinicians. The platform addresses a critical inefficiency where traditional radiology-style workflows capture only about 15% of compliant studies, meaning up to 85% go unbilled, with Compass AI capable of translating that into as much as five times more revenue from the same clinical volume.
“Health systems want to expand POCUS and capture more value, but they’ve been held back by undocumented exams, compliance risk and administrative burden that take clinicians away from patients,” said Joseph DeVivo, President, CEO and Chairman of Butterfly Network. “Compass AI changes that. It gives organizations the workflows and interoperability to manage POCUS programs at scale — no blind spots, no fragmented care, no added risk. To me, it’s a path to easy money: capturing value that was already there, just being missed.”
The platform features a Documentation Agent with ambient voice dictation that cuts charting time by up to 25%, a QA Agent that streamlines quality assurance through AI-powered image review, a Program Dashboard that tracks usage, compliance, credentialing and unbilled scans while surfacing potential ROI, and seamless integration with EHRs, PACS and SSO. Beyond documentation, Compass AI works across departments and ultrasound devices to provide health systems with the visibility and governance needed to scale POCUS from siloed tools into a coordinated imaging service, strengthening profitability, compliance, and care quality in real time.
NANOX Imaging Ltd. (NASDAQ: NNOX) has secured a distribution collaboration with Althea France SARL, part of one of Europe’s largest independent medical technology services providers, to introduce its CE-marked Nanox.ARC multi-source digital tomosynthesis system across the French healthcare sector. This partnership marks Nanox’s fourth European distribution agreement following recent collaborations in Greece, Romania and the Czech Republic, positioning the company to expand access to its advanced 3D imaging technology that provides enhanced diagnostic capabilities at lower cost than traditional systems.
“France is a key strategic market for Nanox, and Althea’s leadership position and deep expertise in imaging technology management make them an excellent partner for our growth,” said Erez Meltzer, CEO and Acting Chairman of Nanox. “We look forward to working with the Althea France team, whose nationwide footprint and strong relationships with university hospitals, public hospitals and private clinic networks will enable us to introduce our comprehensive imaging platform and expand access to high-quality, affordable imaging services for patients throughout France.”
Althea Group’s extensive infrastructure manages thousands of medical imaging devices across France and delivers comprehensive lifecycle support from installation to performance optimization.
Schrödinger, Inc. (NASDAQ: SDGR) delivered strong third quarter 2025 results with total revenue of $54.3 million, representing 54% growth year-over-year, driven by software revenue of $40.9 million (up 28%) and drug discovery revenue of $13.5 million compared to $3.4 million in the prior year period. The computational platform company maintained a 73% software gross margin while reducing operating expenses to $74.0 million from $86.2 million year-over-year, with cash, cash equivalents and marketable securities of approximately $785 million as of October 9, 2025, providing runway through the end of 2027.
“In our therapeutics portfolio, we are continuing to make strong progress advancing our collaborations and have increased our expectations for drug discovery revenue this year,” said Ramy Farid, Ph.D., CEO of Schrödinger. “These actions, coupled with expense-reduction measures we undertook earlier this year, are expected to result in savings of approximately $70 million and improve our operational efficiency and long-term profitability profile.”
The company’s therapeutics pipeline includes SGR-3515, a Wee1/Myt1 co-inhibitor in Phase 1 with initial clinical data expected in the first half of 2026, SGR-1505, a MALT-1 inhibitor that received Orphan Drug Designation for Waldenström macroglobulinemia, and SGR-7735, a recently nominated PI3Kα H1047R inhibitor development candidate now in IND-enabling studies. Schrödinger updated its 2025 full-year guidance to software revenue growth of 8% to 13% (from 10% to 15% previously), drug discovery revenue of $49 million to $52 million (from $45 million to $50 million), and software gross margin of 73% to 75%, while advancing multiple partnered programs with Roche, Genentech and Sanofi across neuroscience, oncology and immunology indications.
Article Sources: https://equity-insider.com/2025/10/31/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
CONTACT:
USA NEWS GROUP
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval.
—
SOURCES:
- https://www.globenewswire.com/news-release/2025/11/25/3194434/28124/en/Precision-Medicine-Strategic-Intelligence-Report-2025-Opportunities-in-Integrating-AI-and-Bioinformatics-to-Predict-Disease-Risks-Enhance-Diagnostics-and-Shape-Personalized-Care.html
- https://orthospinenews.com/2025/11/07/artificial-intelligence-in-healthcare-market-to-surge-across-usa-europe-apac-and-saudi-arabia-by-2035/
- https://www.scnsoft.com/healthcare/healthcare-ai-trends
